Sugammadex sodium 99%
2 Inquiries
343306-79-6
Pharmaceutical Grade
99%
SHANGHAI
1kg/1.3kg Carton
2040-02-01
Imatinib mesylate
-
Product Description
-
Seller Information
-
Inquiry History
-
Description
To facilitate tracheal intubation, mechanical ventilation, and surgical access, NMB agents are frequently used as non-anesthetic adjuncts in surgical procedures. Sugammadex is able to function as a pharmacologic sink of rocuronium and vecuronium, another non-depolarizing neuromuscular blocker, without the cardiovascular adverse effects experienced with reversal agents that directly interact with the cholinergic system. The γ-cyclodextrin has been designed to enhance binding of the guest by incorporating acidic side chains to promote an electrostatic interaction with the positive nitrogen of the blocker. Starting with γ-cyclodextrin, these side chains are readily installed by first halogenating with iodine or bromine to provide a handle for nucleophilic displacement with either 3-mercaptopropionic acid in the presence of sodium hydride or with 3-mercaptopropionic acid methyl ester and cesium carbonate. The latter requires hydrolysis with sodium hydroxide to generate sugammadex sodium.
Basic Info-
Product Name:
Org 25969
Other Name:γ-Cyclodextrin,6A,6B,6C,6D,6E,6F,6G,6H-octakis-S-(2-carboxyethyl)-6A,6B,6C,6D,6E,6F,6G,6H-octathio-,sodium salt (1:8);γ-Cyclodextrin,6A,6B,6C,6D,6E,6F,6G,6H-octakis-S-(2-carboxyethyl)-6A,6B,6C,6D,6E,6F,6G,6H-octathio-,octasodium salt;Org 25969;Sugammadex sodium;6-Per-deoxy-6-per-(2-carboxyethyl)thio-γ-cyclodextrin sodium salt;Sugammadex sodium salt;862667-16-1;1202253-72-2
CAS No.:343306-79-6
Molecular Formula:C72H112O48S8.8Na
InChIKeys:InChIKey=JAHOWADERQMFIV-VKHHSAQNSA-N
Molecular Weight:2177.974
Exact Mass:2176.26000
EC Number:608-974-4
UNII:ERJ6X2MXV7
NCI Thesaurus Code:C78123
ATC Code:V03AB35|V - Various
Characteristics-
PSA:
995
Density:1.275g/cm3 (计算值)
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
GHS label elements, including precautionary statements
Pictogram(s)
Signal word Warning
Hazard statement(s) H302 Harmful if swallowed
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Imatinib mesylate
-
Location:
No.21,HuanCheng West Road ,AnQing City ,Anhui Province,China
-
Payment Terms:
D/P,L/C,D/A
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2009
-
Certifications:
business license,ISO9001
ANHUI HAIKANG PHARMACEUTICAL CO.,LTD. was established in 2009 in Anqing City, Anhui Province. It is located along the north bank of mid and lower reaches of the Yangtze River. Enjoying favorable geographic superiorities and convenient transportation infrastructure: such as highway, high speed railway, airport, inland shipping container terminal and so on. By plane, it takes just 1 hour to Shanghai, 2 hours to Guangzhou or Beijing; by high speed train it takes 2 hours to reach Nanjing, 4 hours to Shanghai, 6.5 hours Beijing.Since founded the company has been committed to the production, sales and export of chemical raw materials of pharmaceutical APIs and intermediates, while as well as other services of product customization, process improvement, achievement transfer,etc.
The company covers an area of 28000 square meters. We invested 80 million Yuan to set up 3 synthesis workshops and 3 purification workshops, whose annual output value is over hundred million Yuan, and their profits and taxes are over 20 million Yuan. All our productions are in strict accordance with GMP standard and we have established a well-equipped R & D center.
Haikang currently employs 50 people. 2 of them are of doctoral degree, 6 of master degree,1 researcher returned from overseas and all the rest employees have at least college education. We have close cooperation with Zhejiang University of Technology, University of Science and Technology of China and Anhui University of Chinese Medicine ,etc. We have an academic advisors team consisting of experts and professors who have well background of medical profession and ample experience in pharmacy developing and marketing. It is a united, hard-working, courageous, rigorous and innovative team of elites.
Through years of unremitting efforts Haikang has made remarkable achievements in the R&D and production of anti-virus, antidiabetic series APIs and intermediates. The main products are ganciclovir, valganciclovir hydrochloride, valaciclovir HCL, silodosin, repaglinide, sitagliptin, imatinib and their intermediates. We have established long and stable relationship with nearly 100 domestic and international pharmaceutical manufacturers and research institutes.
To deal with increasingly fierce competition and challenges of economic globalization, Haikang adheres to the business philosophy of “Customer is First, Technology is Leading, Quality is Everything, Honesty for Development” and insists on developing scientifically, globally and diversely. Relying on our existing advantages, we focus on the integration of various resources, and actively optimize the system of decision-making, management and service. We keep up with the pace of the newest R&D trend in and outside China; keep continuous innovation to develop high-tech, market prospective products to satisfy different needs from different customers. While pursuing economic benefits, Haikang has also committed to spare no efforts to advanced environmental management. It is always a mission and moreover a responsibility for Haikang to take care of people’s health and protect the environment.
We have confidence in our future and looking forward to having sincere, win-win and brilliant cooperation with you!
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted
India
Sugammadex Sodium 343306-79-6
1 KG May 28, 2026
India
Bromocriptine mesylate
100 G May 28, 2026 Post an enquiry for this product